Interpace Biosciences, Inc. (IDXG) Operating margin 2016–2025
Interpace Biosciences, Inc. (IDXG) operating margin by fiscal year — reported operating income divided by reported revenue.
10.5%FY2025 · since FY2016: -49.2% → 10.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 10.5% | -6.7 pp |
| FY2024 | 17.3% | +7.4 pp |
| FY2023 | 9.9% | +21.2 pp |
| FY2022 | -11.4% | +7.8 pp |
| FY2021 | -19.1% | +61.3 pp |
| FY2020 | -80.5% | +28.7 pp |
| FY2019 | -109.1% | -51.5 pp |
| FY2018 | -57.7% | -18.1 pp |
| FY2017 | -39.6% | +9.6 pp |
| FY2016 | -49.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice